Medicare seniors get drug discounts—but only if plans pass them on
H.R. 1244 — Reducing Drug Prices for Seniors Act · Filed by Donald Davis (D-NC) · 2 cosponsors · Introduced Feb 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare Part D drug plans to calculate patient coinsurance (the percentage of drug cost patients pay) based on the actual negotiated price a plan pays for a drug, rather than the higher wholesale acquisition cost list price. Starting in 2026, when a drug's real negotiated price is lower than its list price, seniors will pay coinsurance on the lower amount, reducing their out-of-pocket costs for drugs where plans have negotiated discounts.
Why we flagged it
The bill's sole operative mechanism is a cost-sharing calculation change that reduces senior out-of-pocket expenses for drugs where plans have negotiated discounts. It is a straightforward consumer-protection measure targeting drug affordability.
What the text implies
- Plans may respond by adjusting formulary placement or copayment structures for drugs where actual acquisition cost is significantly lower than WAC, potentially shifting cost-sharing to other tiers or drugs not covered by this rule.
- The rule applies only when actual acquisition cost is lower than wholesale acquisition cost; for drugs where negotiated prices exceed list prices (rare but possible), coinsurance remains based on WAC, creating a one-way ratchet.
The full analysis lists 4 implications of this text.
Who stands to gain
Medicare beneficiaries (seniors) — reduced out-of-pocket drug costs